Prediction Model for the Recanalization OuTcome Evaluation of Ischemic Stroke Using Multimodal CT

Stroke, Acute Clinical Trial

— PROTECT  

Official title:

Prediction Model for the Recanalization Outcome Evaluation of Ischemic Stroke Using Multimodal CT

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03670862
• Other study ID #: PROTECT-ChinaPLAGH
• Status: Completed
• Start date: January 1, 2019
• Est. completion date: March 30, 2021

Study information

• Verified date: September 2021
• Source: Chinese PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Prediction model for the Recanalization OuTcome Evaluation of ischemic stroke using multimodal CT (PROTECT) study was a multicenter prospective observational study that recruited patients from 13 centers located in 10 provinces across China. The study was to assess the effects of novel imaging biomarkers/ imaging patterns based on multimodel CT for patients selection and outcome prediction in acute ischemic stroke.

Description:

Patients Patients with cerebral ischemia symptoms of anterior circulation or posterior circulation onset in 24 hours were included. A neurological evaluation (Modified Rankin Scale and NIHSS); physical examination, including measurement of weight (kg) and vital signs (supine systolic and diastolic blood pressure); time from symptom onset to enrollment were recorded. Imaging protocols: CT scan protocols: Non-contrast computed tomography(NCCT) , computed tomography angiography(CTA), computed tomography perfusion(CTP) Contrast agent: CTA: Omniscan 40-50ml, 5ml/s; saline solution 50ml, 5ml/s CTP: Omniscan 50ml, 5ml/s; saline solution 50ml, 5ml/s Imaging evaluation: CTA was reviewed and stenosis or occlusive lesions were identified. Parameter maps including cerebral blood flow, cerebral blood volume, mean transit time, the time to the maximum of the residue function derived from CTP were processed by the software Rapid to quantitatively assess infarct core volume and mismatch. Multiphase CTA was extracted from CTP to evaluate the collateral circulation. Treatment: Intravenous recombinant tissue plasminogen activator(rtPA), endovascular therapy, and conventional treatment including neuroprotection, anti-platelet, and statin according to the guideline. Follow up: Modified Rankin Scale(mRS) was obtained at 90 days after symptom onset. An imaging follow-up was also recommended within 30 days after symptom onset.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 862
• Est. completion date: March 30, 2021
• Est. primary completion date: March 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cerebral ischemic sympton with onset in 24 hours
• All CT examination performed according to study protocol
• Signed informed consent obtained from the patient or patient's legally authorized representative

Exclusion Criteria:

• Acute intracranial hemorrhage
• Pre-existing medical, the neurological, or psychiatric disease that would confound the neurological, functional, or imaging evaluations
• Pregnancy
• Known allergy to iodine previously refractory to pretreatment medications
• Renal Failure (serum creatinine > 2.0 or Glomerular Filtration Rate < 30)
• History of severe kidney disease as an adult, including tumor or transplant surgery, or family history of kidney failure
• Severe cardiac insufficiency

Related Conditions & MeSH terms

• Ischemic Stroke
• Stroke
• Stroke, Acute

Intervention

Other:
• CT
Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	90-day functional outcome	Assessed by modified Rankin Scale with scores ranging from 0 (no symptoms) to 6 (death)	90 days after symptom onset
Secondary	Final infarction volume	Finding the predictive value of novel imaging biomarkers/ imaging patterns on final infarction volume	within 30 days after symptom onset
Secondary	Percentage of Hemorrhagic Transformation	Symptomatic hemorrhagic transformation after acute ischemic stroke	within 7 days after symptom onset